Tumefactive Demyelinating Brain Lesion Developing after Administration of Adenovector-Based COVID-19 Vaccine: A Case Report.
Neurol India
; 70(1): 409-411, 2022.
Article
in English
| MEDLINE | ID: covidwho-1726256
ABSTRACT
Background:
Postmarketing surveillance of COVID-19 vaccination reveals that the COVID-19 vaccine administration is associated with several rare but serious neurological complications. Case Report We report a case of new-onset tumefactive demyelinating brain lesion that developed after administration of an adenovector-based COVID-19 vaccine. A middle-aged female presented with recent right hemiparesis, which was noticed 2 days after she received the first dose of the vaccine. Magnetic resonance imaging (MRI) revealed a large subcortical T2/FLAIR hyperintensities involving corpus callosum as well. The patient responded to oral methylprednisolone. At 4 weeks, a follow-up MRI revealed a reduction in size of the lesion.Conclusion:
To conclude, adenovector-based COVID-19 vaccination may be associated with a tumefactive demyelinating lesion.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Demyelinating Diseases
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Case report
/
Cohort study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Neurol India
Year:
2022
Document Type:
Article
Affiliation country:
0028-3886.338642
Similar
MEDLINE
...
LILACS
LIS